List of Excipients in Branded Drug STARLIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	CROSCARMELLOSE SODIUM
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	HYPROMELLOSE 2208
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	LACTOSE MONOHYDRATE
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	MAGNESIUM STEARATE
Novartis Pharmaceuticals Corporation	STARLIX	nateglinide	0078-0351	POLYETHYLENE GLYCOL

Starlix (Nateglinide) Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Starlix is the branded form of nateglinide, an oral meglitinide insulin secretagogue approved by the FDA for improving glycemic control in adults with type 2 diabetes. Its commercial exclusivity has ended, and the product has limited strategic value as a branded prescription asset. The strongest opportunities are generic manufacturing, differentiated excipient systems, regional supply, fixed-dose combinations, and low-cost oral solid-dose production.

Nateglinide is a small-molecule immediate-release tablet available historically in 60 mg and 120 mg strengths. Because the product is not a biologic, biosimilar competition is irrelevant. The principal barriers are bioequivalence, formulation robustness, market access, manufacturing cost, and differentiation in a crowded diabetes market.

What is Starlix and how is nateglinide formulated?

Starlix contains nateglinide, a D-phenylalanine derivative that stimulates rapid, short-duration insulin release around meals. The product is administered before meals and is designed for immediate release rather than sustained exposure.

Attribute	Starlix
Active ingredient	Nateglinide
Drug class	Meglitinide insulin secretagogue
Dosage form	Immediate-release film-coated tablet
Historical strengths	60 mg and 120 mg
Original sponsor	Novartis
FDA application	NDA 021204
Original FDA approval	2000
Primary indication	Type 2 diabetes mellitus
Generic pathway	ANDA, subject to FDA bioequivalence requirements
Biosimilar pathway	Not applicable
Primary commercial issue	Generic competition and declining branded differentiation

The label-reported inactive-ingredient system includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, colloidal silicon dioxide, talc, and strength-specific colorants or coating materials. Exact excipient composition should be confirmed against the applicable FDA label and manufacturer filing because commercial versions can use different inactive ingredients while maintaining pharmaceutical equivalence [1].

What excipients protect the Starlix formulation?

No commercially significant Starlix exclusivity appears to depend on a distinctive excipient platform. The formulation is based on standard immediate-release tablet excipients:

Excipient	Functional role	Commercial relevance
Lactose monohydrate	Diluent and tablet mass builder	Low cost, but creates lactose and dairy-origin positioning issues
Microcrystalline cellulose	Dry binder and compressibility aid	Supports direct compression and tablet mechanical strength
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Povidone	Binder	Controls granule or compact strength
Magnesium stearate	Lubricant	Improves ejection but can slow wetting if over-lubricated
Colloidal silicon dioxide	Glidant and anti-caking agent	Improves powder flow
Talc	Processing aid or coating component	Can influence powder flow and coating performance
Iron oxide or other colorants	Strength identification	Supports differentiation and medication-error reduction

The formulation strategy is conventional. Its value comes from balancing rapid disintegration, adequate hardness, low manufacturing cost, and consistent dissolution. The product does not require a complex modified-release matrix, lipid system, amorphous dispersion, nanocrystal platform, or device component.

What formulation properties matter most?

The critical development target is rapid and reproducible dissolution. Nateglinide tablets must disperse consistently despite potential sensitivity to:

• Compression force
• Lubrication time and magnesium stearate level
• Particle-size distribution
• API polymorphism or solid-state form
• Moisture exposure
• Granulation endpoint
• Coating weight
• Tablet hardness
• Storage humidity

A generic manufacturer can often achieve cost advantages through direct compression if the API has suitable flow and compaction properties. If nateglinide powder has inadequate flow or poor compactability, a dry-granulation process can provide more reliable scale-up than direct compression.

What excipient strategy is best for generic nateglinide?

The most practical strategy is a conventional immediate-release platform with targeted excipient substitution rather than a radical reformulation.

Strategy 1: Q1/Q2-equivalent formulation

A generic sponsor can use the reference product’s inactive ingredients at the same or substantially similar levels. This approach reduces regulatory and bioequivalence risk. It is suitable where:

• The reference product’s composition is adequately characterized.
• The API has predictable dissolution.
• The sponsor wants a conventional ANDA path.
• Manufacturing cost is more important than product differentiation.

This route offers the fastest development path but creates limited commercial distinction.

Strategy 2: Lactose-free formulation

Replacing lactose with mannitol, dibasic calcium phosphate, anhydrous calcium phosphate, or additional microcrystalline cellulose can support a lactose-free product. The commercial case is strongest in markets where pharmacies and patients value excipient transparency or where lactose intolerance concerns influence product selection.

The principal technical risks are altered tablet density, mouthfeel, compactability, dissolution, and hygroscopicity. Mannitol can improve sensory properties but may increase cost. Calcium phosphate can improve hardness but may alter disintegration and compression behavior.

Strategy 3: Low-moisture formulation

A low-moisture formulation can use anhydrous diluents, controlled-humidity processing, and moisture-barrier packaging. This approach is relevant if nateglinide or the selected excipient system shows hydrolytic or physical instability.

Potential commercial claims include improved storage resilience and suitability for hot, humid markets. Such claims require comparative stability data and cannot be assumed from excipient selection alone.

Strategy 4: Direct-compression platform

Direct compression can reduce:

• Water consumption
• Granulation time
• Equipment requirements
• Labor
• Batch cycle time
• Microbial-control burden

The principal development challenge is achieving consistent blend uniformity at a low drug load. Nateglinide represents a meaningful portion of tablet mass in the 60 mg and 120 mg strengths, which may support direct compression, but powder flow and segregation still require evaluation.

Strategy 5: Rapid-disintegration tablet

A higher-performance disintegrant system could produce faster tablet breakup and more consistent dissolution. Candidates may include croscarmellose sodium, crospovidone, or sodium starch glycolate, used alone or in combination.

This strategy has limited patent value unless linked to a demonstrably novel formulation, dissolution profile, stability advantage, or clinical benefit. A simple change in superdisintegrant is unlikely to create durable market exclusivity on its own.

What patents protect Starlix and when does nateglinide lose exclusivity?

The original nateglinide compound and early-use patent estate are no longer expected to provide a meaningful U.S. market barrier. Starlix is a small molecule approved in 2000, and the relevant ordinary patent terms would have expired years ago, subject to any applicable patent-term adjustment or extension.

Exclusivity category	Starlix status
New chemical entity exclusivity	Expired
Original compound patent estate	Expired or commercially non-blocking
FDA pediatric exclusivity	No current commercial effect
Active Orange Book formulation barrier	No material current barrier identified
Biosimilar exclusivity	Not applicable
Generic entry	Available through ANDA competition

The U.S. Orange Book remains the controlling source for current listed patents and regulatory exclusivities. A commercial diligence review should distinguish between an expired historical patent, an unexpired listed patent, and a patent that is listed but does not cover the proposed generic product [2].

What is the Orange Book status of Starlix?

NDA 021204 is associated with Starlix and nateglinide tablets. The product’s practical regulatory status is that of an older small-molecule reference drug with generic competition rather than an innovator product protected by current data or market exclusivity.

For a generic applicant, the relevant questions are:

1. Whether Starlix remains the reference listed drug for the proposed strength.
2. Whether an FDA-designated reference standard is required.
3. Whether any current Orange Book patent listing applies to the specific strength or dosage form.
4. Whether the application requires a Paragraph IV certification or a different certification.
5. Whether the reference product has been discontinued for reasons other than safety or effectiveness.

FDA approval of a nateglinide ANDA does not automatically establish commercial interchangeability in every market. State substitution rules, payer formularies, national procurement systems, and local regulatory requirements remain relevant.

Are there Paragraph IV challenges to Starlix?

Nateglinide has been subject to generic development and approval activity, but the commercial significance of Paragraph IV litigation is limited because the core exclusivity period has expired. A Paragraph IV certification is most relevant when an ANDA applicant challenges an unexpired Orange Book patent. If no blocking patent remains, an ANDA applicant may rely on other certification pathways.

No active, material Starlix Paragraph IV dispute is identified in the principal FDA sources cited here. Historical patent litigation, if any, does not create a current market barrier unless an enforceable patent remains in force.

The absence of a current patent dispute shifts the competitive focus to:

• ANDA approval timing
• Product quality
• API sourcing
• Price
• Supply reliability
• Distributor contracts
• Formulary access
• International registrations

What generic entry risks exist for nateglinide?

The generic-entry risk is high for any remaining branded nateglinide product. The product is an established oral tablet with a conventional formulation and no biologic manufacturing complexity.

Regulatory risk

Bioequivalence must be demonstrated against the applicable reference product. Dissolution similarity is particularly important because nateglinide is an immediate-release product intended for use around meals. Formulation changes that affect wetting, disintegration, or dissolution can create avoidable development risk.

Manufacturing risk

The key manufacturing risks are:

• API particle-size variability
• Blend segregation
• Over-lubrication
• Tablet capping or lamination
• Coating defects
• Humidity-driven stability changes
• Inconsistent dissolution after scale-up

Commercial risk

Nateglinide competes with generic repaglinide, sulfonylureas, metformin, DPP-4 inhibitors, GLP-1 products, SGLT2 inhibitors, and insulin products. The product’s short duration and meal-linked dosing can support a niche position, but it does not have the commercial growth profile of newer diabetes classes.

What commercial opportunities exist for Starlix excipients?

The most credible opportunities are manufacturing and portfolio-based rather than premium branded reformulation.

Generic contract manufacturing

A CDMO can offer nateglinide as part of a broader oral antidiabetic portfolio. The product fits standard tablet infrastructure and can be bundled with metformin, glimepiride, glipizide, or repaglinide manufacturing capabilities.

Regional low-cost supply

Nateglinide may remain commercially relevant in price-sensitive markets where newer diabetes drugs have limited reimbursement. A manufacturer with low-cost API access, efficient tableting, and local registration capability can compete through supply reliability and price.

Lactose-free and excipient-transparent products

A lactose-free version can address procurement specifications, patient preference, or distributor requirements. This is a positioning advantage rather than a strong exclusivity strategy.

Fixed-dose combinations

A fixed-dose combination with another oral antidiabetic could create a lifecycle opportunity, but it would require a clinically and commercially credible dosing rationale. Combination development would face:

• New bioequivalence requirements
• Compatibility and stability studies
• Dose-ratio constraints
• Additional labeling review
• Competition from established combination products

Packaging and adherence systems

Calendar blister packs, meal-linked labeling, and unit-dose packaging may improve product usability. These features are more likely to create commercial differentiation than a basic excipient change, although they generally provide weak patent protection.

How does Starlix compare with competing diabetes drugs?

Product class	Primary advantage	Main disadvantage versus nateglinide	Commercial implication
Metformin	Low cost and broad use	Gastrointestinal tolerability and contraindication limits	Stronger generic demand
Repaglinide	Similar meal-time insulin secretagogue	Competes directly on dosing behavior	Direct therapeutic substitute
Sulfonylureas	Low cost and broad availability	Hypoglycemia and weight-gain concerns	Strong price competition
DPP-4 inhibitors	Oral dosing and lower hypoglycemia risk	Higher cost and patent history	Stronger branded differentiation
GLP-1 receptor agonists	Weight-loss and glycemic benefits	Injectable or specialized oral products, higher cost	Premium segment
SGLT2 inhibitors	Cardiovascular and renal outcomes	Higher cost and class-specific safety concerns	Strong reimbursement-driven competition

Nateglinide’s strongest commercial position is as an inexpensive, conventional oral therapy for patients requiring meal-related glycemic control. Its weakest position is in markets where outcome-based diabetes therapies receive preferential reimbursement.

What is the patent strength of a new nateglinide formulation?

A basic excipient substitution would have weak patent strength. Stronger protection would require a defensible technical feature, such as:

• A defined polymorph or co-crystal
• A novel particle-size distribution
• A validated dissolution-control system
• A stability-enhancing composition
• A clinically meaningful modified-release profile
• A novel fixed-dose combination
• A manufacturing process that materially improves purity or yield

Even then, patent value would depend on claim scope, freedom-to-operate analysis, enablement, obviousness risk, and the commercial size of the nateglinide market. A narrow formulation patent may be enforceable but economically unattractive if generic competitors can design around it.

What manufacturing and intellectual-property barriers remain?

The manufacturing barrier is moderate to low. Standard oral solid-dose equipment is sufficient, and the excipient system relies on widely available materials. The principal barriers are executional:

• Consistent API quality
• Robust blend and compression performance
• Dissolution matching
• Stability in global climate zones
• Reliable packaging
• Regulatory documentation
• API supplier qualification

The intellectual-property barrier is low for the core product. New IP is more likely to protect a process, solid form, combination, or specialized formulation than the original nateglinide tablet.

Key Takeaways

• Starlix is the branded nateglinide immediate-release tablet, historically marketed in 60 mg and 120 mg strengths.
• Its excipient system is conventional and includes a diluent, binder, superdisintegrant, lubricant, glidant, and coating or colorant components.
• The core compound and original Starlix exclusivity have expired; current U.S. commercial barriers are limited.
• Biosimilar risk does not apply because nateglinide is a small molecule.
• Generic development is feasible through a conventional ANDA strategy.
• The best excipient opportunities are lactose-free, low-moisture, direct-compression, and rapid-disintegration formulations.
• A simple excipient substitution is unlikely to create strong patent protection.
• Commercial value is concentrated in low-cost manufacturing, regional supply, contract development, and portfolio packaging.
• Nateglinide faces substantial competition from generic oral antidiabetics and newer outcome-driven diabetes therapies.
• A new formulation would need a measurable stability, dissolution, adherence, or clinical advantage to justify development investment.

FAQs

Can nateglinide tablets be manufactured without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent. The replacement requires comparative dissolution, stability, manufacturability, and bioequivalence assessment.

Is Starlix a biologic drug requiring biosimilar competition analysis?

No. Starlix contains nateglinide, a chemically synthesized small molecule. Competition proceeds through generic drug pathways, primarily ANDAs in the United States.

Can a new nateglinide formulation receive patent protection?

Potentially, but a patent would need claims directed to a non-obvious and technically supported formulation, solid form, process, combination, or delivery system. Routine excipient substitution generally presents weak patentability.

Is nateglinide suitable for direct-compression manufacturing?

It may be suitable if the API and excipient blend provide adequate flow, content uniformity, compactability, and dissolution. Process selection must be confirmed through formulation and scale-up studies.

Does Starlix still have meaningful branded revenue potential?

Limited branded upside is expected because of generic competition, expired core exclusivity, and competition from newer diabetes therapies. The stronger opportunity is low-cost generic supply or a differentiated regional formulation.

References

1. U.S. Food and Drug Administration. (2000). Starlix (nateglinide) tablets prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/

4. U.S. National Library of Medicine. (n.d.). DailyMed: Nateglinide and Starlix labeling. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (n.d.). ANDA approvals and generic drug guidance. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drug-approval-process-stages-and-time-lines